3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,236 as of Thursday, Feb. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,761 issues advancing vs. 1,149 declining with 174 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.6%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Perrigo Company ( PRGO), up 1.2% and Novartis ( NVS), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Incyte ( INCY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Incyte is down $1.06 (-1.6%) to $66.20 on light volume. Thus far, 607,215 shares of Incyte exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $65.98-$68.27 after having opened the day at $66.96 as compared to the previous trading day's close of $67.26.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $11.3 billion and is part of the health care sector. Shares are up 32.9% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Incyte Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Questcor Pharmaceuticals ( QCOR) is down $4.30 (-5.8%) to $69.91 on heavy volume. Thus far, 3.9 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $69.02-$73.58 after having opened the day at $73.48 as compared to the previous trading day's close of $74.21.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $4.8 billion and is part of the health care sector. Shares are up 36.3% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Questcor Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.49 (-0.6%) to $83.32 on light volume. Thus far, 3.8 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $82.50-$83.95 after having opened the day at $83.65 as compared to the previous trading day's close of $83.81.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $128.7 billion and is part of the health care sector. Shares are up 11.6% year-to-date as of the close of trading on Wednesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Get to Know Stacey Cunningham, the NYSE's First Female Chief in 226 Years

Get to Know Stacey Cunningham, the NYSE's First Female Chief in 226 Years

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know